Monotonicity of interleukin-1 receptor-ligand binding with respect to antagonist in the presence of decoy receptor

Journal of Theoretical Biology

Volumn 244, Issue 3, 2007, Pages 478-488

  Gnacadja, Gilles ^a   Shoshitaishvili, Alex ^a   Gresser, Michael J ^b   Varnum, Brian ^a   Balaban, David ^a   Durst, Mark ^a   Vezina, Chris ^a   Li, Yu ^a  

^a AMGEN INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemical reaction network; Decoy receptor; Equilibrium; Interleukin 1; Monotonicity; Trap

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LIGAND;

EQUILIBRIUM; LIGAND; PROTEIN;

ARTICLE; CHEMICAL REACTION; CHEMICAL REACTION NETWORK; INFLAMMATION; LIGAND BINDING; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; PRIORITY JOURNAL; REACTION ANALYSIS;

ANIMALS; ARTHRITIS, RHEUMATOID; BINDING SITES; BINDING, COMPETITIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; MODELS, BIOLOGICAL; MODELS, CHEMICAL; RECEPTORS, INTERLEUKIN-1; RECOMBINANT PROTEINS;

EID: 33845905498     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2006.07.023     Document Type: Article

References (26)

1. Bresnihan B., Alvaro-Gracia J.M., Cobby M., Doherty M., Domljan Z., Emery P., Nuki G., Pavelka K., Rau R., Rozman B., Watt I., Williams B., Aitchison R., McCabe D., and Musikic P. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 41 12 (1998) 2196-2204
2. Burger D., Chicheportiche R., Giri J.G., and Dayer J.-M. The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor. J. Clin. Invest. 96 (1995) 38-41
3. Bywater R.P., Sorensen A., Rogen P., and Hjorth P.G. Construction of the simplest model to explain complex receptor activation kinetics. J. Theor. Biol. 218 (2002) 139-147
4. Chaves M., Sontag E.D., and Dinerstein R.J. Steady-states of receptor-ligand dynamics: a theoretical framework. J. Theor. Biol. 227 (2004) 413-428
5. Cornish-Bowden A. Fundamentals of Enzyme Kinetics. third ed. (2004), Portland-Press
6. Dinarello C.A. Biologic basis for interleukin-1 in disease. Blood 87 6 (1996) 2095-2147
7. Economides A.N., Carpenter L.R., Rudge J.S., Wong V., Koehler-Stec E.M., Hartnett C., Pyles E.A., Xu X., Daly T., Young M.R., Fandl J.P., Lee F., Carver S., McNay J., Bailey K., Ramakanth S., Hutabarat R., Huang T.T., Radziejewski C., Yancopoulos G.D., and Stahl N. Cytokine traps: multi-component high-affinity blockers of cytokine action. Nat. Med. 9 1 (2003) 47-52
8. Feinberg, M., 1980. Lectures on chemical reaction networks 〈http://www.che.eng.ohio-state.edu/∼Feinberg/LecturesOnReactionNetworks/〉.
9. Feinberg M. Chemical reaction network structure and the stability of complex isothermal reactors-I. The deficiency zero and deficiency one theorems. Chem. Eng. Sci. 42 10 (1987) 2229-2268
10. Feinberg M. Chemical reaction network structure and the stability of complex isothermal reactors-II. Multiple steady states for networks of deficiency one. Chem. Eng. Sci. 43 1 (1988) 1-25
11. Feinberg M. The existence and uniqueness of steady states for a class of chemical reaction networks. Arch. Ration. Mech. Anal. 132 (1995) 311-370
12. Feinberg M. Multiple steady states for chemical reaction networks of deficiency one. Arch. Ration. Mech. Anal. 132 (1995) 371-406
13. Gatermann K., and Huber B. A family of sparse polynomial systems arising in chemical reaction systems. J. Symb. Comput. 33 (2002) 275-305
14. Guler H.P., Caldwell J.R., Fleischmann R.M., Cohen S.B., Kivitz A.J., Levy R.M., Littlejohn T., McIlwain H., Offenberg H., Papadopoulos J., and Stahl N. Weekly treatment with IL-1 trap is well tolerated and improves ACR criteria in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 61 Suppl. 1 (2002)
15. Gunawardena, J., 2003. Chemical reaction network theory for in-silico biologists 〈http://www.jeremy-gunawardena.com/papers/crnt.pdf〉.
16. Hannum C.H., Wilcox C.J., Arend W.P., Joslin F.G., Dripps D.J., Heimdal P.L., Armes L.G., Sommer A., Eisenberg S.P., and Thompson R.C. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 343 (1990) 336-340
17. Horn F., and Jackson R. General mass action kinetics. Arch. Ration. Mech. Anal. 47 (1972) 81-116
18. Lauffenburger D.A., and Linderman J.J. Receptors: Models for Binding, Trafficking, and Signaling (1996), Oxford University Press, Oxford
19. Limbird L.E. Cell Surface Receptors: A Short Course on Theory and Methods. third ed. (2004), Springer, Berlin
20. Matthews J.C. Fundamentals of Receptor, Enzyme, and Transport Kinetics (1993), CRC, Boca Raton
21. Olszewski W.L., Pazdur J., Kubasiewicz E., Zaleska M., Cooke C.J., and Miller N.E. Lymph draining from foot joints in rheumatoid arthritis provides insight into local cytokine and chemokine production and transport to lymph nodes. Arthritis Rheum. 44 3 (2001) 541-549
22. Siegel D. Monotonicity properties of solutions to systems of differential equations arising in chemical kinetics. In: Dafermos C.M., Ladas G., and Papanicolaou G. (Eds). Differential Equations (1989), Marcel Dekker, New York 637-646
23. Siegel D., and Chen Y.F. Global stability of deficiency zero chemical networks. Can. Appl. Math. Q. 2 3 (1994) 413-434
24. Siegel D., and Lozinski D.W. Monotonicity properties of the Michaelis-Menten reactions of enzyme kinetics. Rocky Mount. J. Math. 20 4 (1990) 1157-1172 G.J. Butler Memorial Conference, Edmonton, Alberta, 1998
25. Siegel D., and MacLean D. Global stability of complex balanced mech anisms. J. Math. Chem. 27 (2000) 89-110
26. Yang B.-B., Baughman S., and Sullivan J.T. Pharmacokinetics of anakinra in subjects with different levels of renal function. Clin. Pharmacol. Ther. 74 1 (2003) 85-94